Literature DB >> 16166416

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.

Kristin K Zorn1, Tomas Bonome, Lisa Gangi, Gadisetti V R Chandramouli, Christopher S Awtrey, Ginger J Gardner, J Carl Barrett, Jeff Boyd, Michael J Birrer.   

Abstract

PURPOSE: The presence of similar histologic subtypes of epithelial ovarian and endometrial cancers has long been noted, although the relevance of this finding to pathogenesis and clinical management is unclear. Despite similar clinical characteristics, histologic subtypes of cancers of the ovary and endometrium are treated according to organ of origin. This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors. EXPERIMENTAL
DESIGN: Gene expression profiles of 75 cancers (endometrioid, serous, and clear cell) of the ovary and endometrium, five renal clear cell cancers, and seven normal epithelial brushings were determined using a 11,000-element cDNA array. All images were analyzed using BRB ArrayTools. Validation was done using real-time PCR on select genes and immunohistochemical staining.
RESULTS: Comparison across endometrial and ovarian cancers and serous and endometrioid tumors showed expression patterns reflecting their organ of origin. Clear cell tumors, however, showed remarkably similar expression patterns regardless of their origin, even when compared with renal clear cell samples. A set of 43 genes was common to comparisons of each of the three histologic subtypes of ovarian cancer with normal ovarian surface epithelium.
CONCLUSIONS: The comparison of the gene expression profiles of endometrioid and serous subtypes of ovarian and endometrial cancer are largely unique to the combination of a particular subtype in a specific organ. In contrast, clear cell cancers show a remarkable similarity in gene expression profiles across organs (including kidney) and could not be statistically distinguished.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166416     DOI: 10.1158/1078-0432.CCR-05-0508

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  135 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

Review 4.  Classification of ovarian cancer: a genomic analysis.

Authors:  Michael P Stany; Tomas Bonome; Fred Wamunyokoli; Kristen Zorn; Laurent Ozbun; Dong-Choon Park; Ke Hao; Jeff Boyd; Anil K Sood; David M Gershenson; Ross S Berkowitz; Samuel C Mok; Michael J Birrer
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

6.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 7.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

Review 8.  Proteomic profiling in ovarian cancer.

Authors:  Geoffrey Kim; Lucas Minig; Elise C Kohn
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

Review 9.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

10.  The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review).

Authors:  Hiroshi Shigetomi; Akira Oonogi; Taihei Tsunemi; Yasuhito Tanase; Yoshihiko Yamada; Hirotaka Kajihara; Yoriko Yoshizawa; Naoto Furukawa; Shoji Haruta; Shozo Yoshida; Toshiyuki Sado; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.